These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 37909949)

  • 1. Skeletal Muscle Mass Before Second-line Chemotherapy Correlates With Subsequent Prognosis and Rate of Late-line Chemotherapy in Patients With Unresectable Gastric Cancer.
    Matsunaga T; Satio H; Sakano YU; Makinoya M; Shimizu S; Shishido Y; Miyatani K; Kono Y; Murakami Y; Hanaki T; Kihara K; Yamamoto M; Tokuyasu N; Takano S; Sakamoto T; Hasegawa T; Fujiwara Y
    Anticancer Res; 2023 Nov; 43(11):5051-5059. PubMed ID: 37909949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of skeletal muscle mass in patients with unresectable gastric cancer who received palliative first-line chemotherapy based on 5-fluorouracil.
    Matsunaga T; Saito H; Miyauchi W; Shishido Y; Miyatani K; Morimoto M; Murakami Y; Hanaki T; Kihara K; Yamamoto M; Tokuyasu N; Takano S; Sakamoto T; Hasegawa T; Fujiwara Y
    BMC Cancer; 2021 Nov; 21(1):1219. PubMed ID: 34774016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of skeletal muscle mass in patients with recurrent gastric cancer.
    Matsunaga T; Satio H; Miyauchi W; Shishido Y; Miyatani K; Murakami Y; Hanaki T; Kihara K; Yamamoto M; Tokuyasu N; Takano S; Sakamoto T; Hasegawa T; Fujiwara Y
    World J Surg Oncol; 2021 Jun; 19(1):170. PubMed ID: 34116681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skeletal Muscle Mass Reduction Velocity as a Simple Prognostic Indicator for Patients with Metastatic Urothelial Carcinoma Receiving Second-Line Chemotherapy.
    Nagai T; Naiki T; Iida K; Nozaki S; Etani T; Sugiyama Y; Ando R; Yanase T; Chaya R; Moritoki Y; Kobayashi D; Akita H; Okamura T; Yasui T
    Asian Pac J Cancer Prev; 2019 Oct; 20(10):2995-3000. PubMed ID: 31653146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of skeletal muscle mass during palliative chemotherapy is a poor prognostic factor in patients with advanced gastric cancer.
    Park SE; Choi JH; Park JY; Kim BJ; Kim JG; Kim JW; Park JM; Chi KC; Hwang IG
    Sci Rep; 2020 Oct; 10(1):17683. PubMed ID: 33077864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapidly declining skeletal muscle mass predicts poor prognosis of hepatocellular carcinoma treated with transcatheter intra-arterial therapies.
    Kobayashi T; Kawai H; Nakano O; Abe S; Kamimura H; Sakamaki A; Kamimura K; Tsuchiya A; Takamura M; Yamagiwa S; Terai S
    BMC Cancer; 2018 Jul; 18(1):756. PubMed ID: 30041616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of sarcopenia with severe chemotherapy toxicities and survival in patients with advanced gastric cancer.
    Chan WL; Yun HB; Cheung EE; Liu M; Hou LY; Lam KO; Wong IY; Chiu WK; Law S; Kwong D
    Oncologist; 2024 Oct; 29(10):e1272-e1279. PubMed ID: 38885304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low Skeletal Muscle Mass before Salvage-Line Chemotherapy Is a Poor Prognostic Factor in Patients with Refractory Metastatic Colorectal Cancer.
    Miyamoto Y; Hiyoshi Y; Akiyama T; Kiyozumi Y; Eto K; Yohei N; Iwagami S; Baba Y; Yoshida N; Baba H
    Digestion; 2019; 99(1):79-85. PubMed ID: 30554226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of skeletal muscle density and sarcopenia in patients with pancreatic cancer undergoing first-line chemotherapy: a retrospective observational study.
    Kim IH; Choi MH; Lee IS; Hong TH; Lee MA
    BMC Cancer; 2021 Jan; 21(1):77. PubMed ID: 33461517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defining reference values for low skeletal muscle index at the L3 vertebra level based on computed tomography in healthy adults: A multicentre study.
    Kong M; Geng N; Zhou Y; Lin N; Song W; Xu M; Li S; Piao Y; Han Z; Guo R; Yang C; Luo N; Wang Z; Jiang M; Wang L; Qiu W; Li J; Shi D; Li R; Cheung EC; Chen Y; Duan Z
    Clin Nutr; 2022 Feb; 41(2):396-404. PubMed ID: 34999334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Skeletal muscle loss during neoadjuvant chemotherapy predicts poor prognosis in patients with breast cancer.
    Amitani M; Oba T; Kiyosawa N; Morikawa H; Chino T; Soma A; Shimizu T; Ohno K; Ono M; Ito T; Kanai T; Maeno K; Ito KI
    BMC Cancer; 2022 Mar; 22(1):327. PubMed ID: 35346102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Change in skeletal muscle index and its prognostic significance in patients who underwent successful conversion therapy for initially unresectable colorectal cancer: observational study.
    Nozawa H; Emoto S; Murono K; Shuno Y; Kawai K; Sasaki K; Sonoda H; Ishii H; Iida Y; Yokoyama Y; Anzai H; Ishihara S
    Therap Adv Gastroenterol; 2020; 13():1756284820971197. PubMed ID: 33240393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of muscle mass loss on outcomes in advanced or metastatic gastric cancer patients receiving a second-line treatment.
    Zurlo V; Rosa F; Rinninella E; Pontolillo L; Beccia V; Maratta M; Tortora G; Alfieri S; Pozzo C; Strippoli A
    Eur Rev Med Pharmacol Sci; 2024 Feb; 28(4):1575-1584. PubMed ID: 38436190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of muscle mass using chest computed tomography-based quantitative and qualitative measurements in patients with systemic sclerosis: A retrospective study with cross-sectional and longitudinal analyses.
    da Rocha DS; Tessari JA; Mainardi NB; Hax V; Gasparin AA; de Oliveira CAV; Garcia TS; Xavier RM; Chakr RMDS
    Semin Arthritis Rheum; 2023 Apr; 59():152168. PubMed ID: 36736023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy.
    Dijksterhuis WPM; Pruijt MJ; van der Woude SO; Klaassen R; Kurk SA; van Oijen MGH; van Laarhoven HWM
    J Cachexia Sarcopenia Muscle; 2019 Feb; 10(1):199-206. PubMed ID: 30666831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index.
    Choi Y; Oh DY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ
    PLoS One; 2015; 10(10):e0139749. PubMed ID: 26437072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Skeletal Muscle Mass Predicts Poor Prognosis in Patients with Advanced Pancreatic Cancer Undergoing Second-Line FOLFIRINOX Chemotherapy.
    Lee HS; Kim SY; Chung MJ; Park JY; Bang S; Park SW; Song SY
    Nutr Cancer; 2019; 71(7):1100-1107. PubMed ID: 30955349
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical Impact of Skeletal Muscle Mass and Nutritional Status in Patients with Recurrent or Advanced Gastric Cancer Treated with Nivolumab.
    Hu Q; Kudo K; Yukaya T; Hasuda H; Nakanishi R; Nakanoko T; Ando K; Ota M; Kimura Y; Koga T; Kusumoto T; Oki E; Yoshizumi T
    Oncology; 2024 Sep; ():1-9. PubMed ID: 39265563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal Cutoff Values of Skeletal Muscle Index to Define Sarcopenia for Prediction of Survival in Patients with Advanced Gastric Cancer.
    Nishigori T; Tsunoda S; Obama K; Hisamori S; Hashimoto K; Itatani Y; Okada K; Sakai Y
    Ann Surg Oncol; 2018 Nov; 25(12):3596-3603. PubMed ID: 30167910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low skeletal muscle density is associated with poor survival in patients who receive chemotherapy for metastatic gastric cancer.
    Hayashi N; Ando Y; Gyawali B; Shimokata T; Maeda O; Fukaya M; Goto H; Nagino M; Kodera Y
    Oncol Rep; 2016 Mar; 35(3):1727-31. PubMed ID: 26648321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.